The recent FDA approval of the Paradise and Symplicity Spyral systems provides a new therapeutic approach to treat resistant hypertension by reducing the activity in the sympathetic nervous system through renal denervation. Both developed after over a decade in development, these devices have been shown to lower blood pressure significantly in patients with hypertension who have not achieved desired results with lifestyle modifications and antihypertensive medications. Both use different methods of ablating the renal nerves, and results suggest a 5-10 mm Hg reduction in systolic blood pressure from baseline. The procedure, which has been shown to be synergistic with other medications, does not work for everyone, and the ideal candidates for treatment include patients with truly resistant hypertension or those unable to take multiple antihypertensive medications, among others.
Source link
How Will It Be Used?
